Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non‐muscle‐invasive bladder cancer
BJUI Compass · 2026-05 · 7 (5)
DOI: 10.1002/bco2.70215 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJUI Compass, online erschienen am 14.05.2026. Verfasst von Jacob Hanna und 10 weiteren Autor:innen. Beteiligte Einrichtung: Rutgers Robert Wood Johnson Medical School New Brunswick New Jersey USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Objectives
This study aimed to evaluate the time toxicity of intravesical BCG compared to sequential intravesical gemcitabine and docetaxel (Gem/Doce) for non–muscle‐invasive bladder cancer (NMIBC). Patients and Methods After IRB approval, we retrospectively reviewed patients with NMIBC treated with BCG or Gem/Doce between 2022 and 2025 at our institution. Medical records were used to calculate time for intravesical therapy, office visits, transurethral resection of bladder tumour (TURBT) and emergency department encounters. Continuous variables were compared using the Wilcoxon rank sum test with Hodges–Lehmann estimates.
Results
Of 133 patients, 86 received BCG (65%) and 47 Gem/Doce (35%). Patients with BCG were more likely treatment naïve compared to those with Gem/Doce (77% vs 55%, p = 0.018). Median time per instillation was 179 min for BCG compared to 192 min for Gem/Doce (Hodges–Lehmann shift +27 min, 95% CI 4 to 57; p = 0.02). Median TURBT time, office visit time and emergency department visit time were similar between groups (all p > 0.05). Over the first six instillations, the cumulative difference was 306 min (+5.1 h, p < 0.001).
Conclusion
Gem/Doce requires a greater time investment than BCG. As effective NMIBC therapies expand, time toxicity should be considered alongside oncologic outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Rutgers Robert Wood Johnson Medical School New Brunswick New Jersey USA.
- Section of Urologic Oncology Rutgers Cancer Institute New Brunswick New Jersey USA.
ORCID-Profile: Jacob Hanna, David Guevara, Thomas Jang
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Hanna, J., Fu, M. Z., Inan, B., Guevara, D., Lannan, L., Patel, D., Hemmati Ghavshough, M., Golombos, D., Jang, T., Ghodoussipour, S., & Packiam, V. T. (2026). Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non‐muscle‐invasive bladder cancer. BJUI Compass, 7(5). https://doi.org/10.1002/bco2.70215
Vancouver
Hanna J, Fu MZ, Inan B, Guevara D, Lannan L, Patel D, et al. Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non‐muscle‐invasive bladder cancer. BJUI Compass. 2026;7(5). doi:10.1002/bco2.70215
BibTeX
@article{Hanna2026,
author = {Hanna, Jacob and Fu, Melinda Z and Inan, Berk and Guevara, David and Lannan, Lucille and Patel, Disha and Hemmati Ghavshough, Mahdi and Golombos, David and Jang, Thomas and Ghodoussipour, Saum and Packiam, Vignesh T},
title = {Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non‐muscle‐invasive bladder cancer},
journal = {BJUI Compass},
year = {2026},
volume = {7},
number = {5},
doi = {10.1002/bco2.70215}
}
EUVIMED